After pioneering the microarray technology used to publish more than 20,000 scientific papers, Affymetrix is evolving into a provider of scalable, innovative genomic analysis tools and reagents for discovery, exploration, validation, and genetic testing. The acquisitions of Panomics and USB bring high-throughput, multi- to single-gene assays and premium-value molecular biology reagents to our customers, enabling a complete solution for genome-wide analysis studies and a range of products for cellular and protein analysis studies.
Researchers around the world use Affymetrix technologies to better understand the role that genes play in disease, the effectiveness and safety of therapies, and many other biological factors that affect human well-being. Affymetrix microarray technology has been used to make groundbreaking discoveries to help the scientific and medical communities investigate conditions such as infertility, HIV, Parkinson's disease, diabetes, malaria, cancer, and many others. Our mission is to revolutionize how the world benefits from genetic information.
Affymetrix contributed significantly to the formation of today's genetic analysis markets, and we will continue to drive the genomics revolution with a single-minded vision: to help all individuals benefit from understanding their own DNA.